Event Information:
Dates
From: 5 June, 2024
To: 8 June, 2024
Location
Milan, Italy
Related Models
TransCure BioServices at EASL 2024: Advancing Liver Research in Milan
TransCure BioServices is thrilled to announce our participation in the upcoming EASL Congress 2024, a leading event dedicated to liver research. Join us in Milan for this pivotal gathering, where the brightest minds in hepatology convene to share their latest findings, innovative research methods, and forward-thinking treatments.
At EASL 2024, TransCure BioServices will be at the forefront, contributing to the dynamic discussions and groundbreaking research presentations. We are committed to enhancing liver disease research through our advanced humanized mouse models, offering new insights into the complexities of liver disorders.
Our presence at EASL underscores our dedication to combatting liver diseases and our continuous effort to support the hepatology community by providing robust preclinical research platforms. We look forward to engaging with fellow researchers, clinicians, and industry professionals to explore new possibilities in liver health, discuss challenges, and uncover solutions that will shape the future of hepatology.
This year, we are excited to have our Business Developer, Ha-Yeon Kim-Penard, PhD, and our Head of Research and Development, Emilie Bayon, PhD, in attendance. Both are eager to exchange ideas, discuss our latest research findings, and explore potential collaborations. Ha-Yeon and Emilie bring a wealth of knowledge and expertise in preclinical research and are looking forward to connecting with attendees to discuss how TransCure’s innovative solutions can support and advance your preclinical research projects.
For more information about our participation in EASL and how TransCure BioServices is contributing to advancements in liver disease research, please contact us.
We can’t wait to meet you in Milan for a week of inspirational scientific exchange and progress in the field of hepatology.
See you at EASL 2024!
Attending in person for TransCure bioServices:
Ha-Yeon Kim-Penard, PhD, Business Development
Ha-Yeon Kim-Penard holds a PhD in Cell and Molecular Biology from the University of Paris, in France. She worked at the Curie Institute (Orsay, France) in the field of cancer biology in cutaneous melanoma, before joining the TransCure bioServices Team as Project Leader in 2020. She has led many in vivo preclinical projects encompassing immuno-oncology, infectious diseases, inflammatory diseases in humanized Immune System and humanized liver mouse models.
Attending in person for TransCure bioServices:
Emilie Bayon, PhD, R&D Immuno-Oncology Team Leader
Emilie Bayon obtained a PhD in Biotechnology from the University Grenoble Alpes through her collaborative work with the French Alternative Energies and Atomic Energy Commission (CEA) on vaccine formulation. Subsequently, she transitioned to TransCure bioServices as a project leader in 2018, before moving to the R&D team. She has contributed to the development of mouse models with humanized immune system and humanized liver, focusing on immuno-oncology, inflammatory and autoimmune diseases, as well as infectious diseases.